Progressive alterations in the hypothalamic-pituitary-adrenal axis in the R6/2 transgenic mouse model of Huntington's disease
The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Huntington's disease (HD) is characterized by a triad of motor, psychiatric and cognitive symptoms. Although many of these symptoms are likely to be related to central nervous system pathology, others may be due to changes in peripheral tissues. The R6/2 mouse, a transgenic model of HD expressing exon 1 of the human HD gene, develops progressive alterations in the hypothalamic-pituitary-adrenal axis, reminiscent of a Cushing-like syndrome. We observed muscular atrophy, reduced bone mineral density, abdominal fat accumulation and insulin resistance in the mice. All these changes could be consequences of increased glucocorticoid levels. Indeed, hypertrophy of the adrenal cortex and a progressive increase in serum and urine corticosterone levels were found in R6/2 mice. In addition, the intermediate pituitary lobe was markedly enlarged and circulating adreno-corticotrophic hormone (ACTH) increased. Under normal conditions dopamine represses the ACTH expression. In the R6/2 mice, however, the expression of pituitary dopamine D2 receptors was reduced by half, possibly explaining the increase in ACTH. Urinary samples from 82 HD patients and 68 control subjects were analysed for cortisol: in accord with the observations in the R6/2 mice, urinary cortisol increased in parallel with disease progression. This progressive increase in cortisol may contribute to the clinical symptoms, such as muscular wasting, mood changes and some of the cognitive deficits that occur in HD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Ultimately, excessive ACTH leads to activation and hypertrophy of the adrenal cortex in aged HD mice, resulting in elevated cortisol levels,367 that may contribute to impaired glucose metabolism,368 skeletal muscle atrophy, and weight loss.369”
From Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances (2025) · cites this paper as [367]
Citations
Cites
Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S. W., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81369-0 · Cited by 3,073
Self-citationDavies, S. W., Turmaine, M., Cozens, B. A., DiFiglia, M., Sharp, A. H., Ross, C. A., Scherzinger, E., Wanker, E. E., Mangiarini, L., & Bates, G. P. (1997) · Cell · doi:10.1016/s0092-8674(00)80513-9 · Cited by 2,181
Self-citationGlucocorticoids and Hippocampal Atrophy in Neuropsychiatric Disorders
Sapolsky, R. M. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.10.925 · Cited by 2,016
Physiology and pharmacology of corticotropin-releasing factor.
Owens, M. J., & Nemeroff, C. B. (1991) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06673-6 · Cited by 1,142
Adult neurogenesis is regulated by adrenal steroids in the dentate gyrus
Cameron, H. A., & Gould, E. (1994) · Neuroscience · doi:10.1016/0306-4522(94)90224-0 · Cited by 998
Carter, R. J., Lione, L. A., Humby, T., Mangiarini, L., Mahal, A., Bates, G. P., Dunnett, S. B., & Morton, A. J. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-08-03248.1999 · Cited by 947
Self-citationHockly, E., Richon, V. M., Woodman, B., Smith, D. L., Zhou, X., Rosa, E., Sathasivam, K., Ghazi-Noori, S., Mahal, A., Lowden, P. A. S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0437870100 · Cited by 845
Self-citationHuntington disease: Clinical care and evaluation
Shoulson, I., & Fahn, S. (1979) · Neurology · doi:10.1212/wnl.29.1.1 · Cited by 746
Sp1 and TAFII130 Transcriptional Activity Disrupted in Early Huntington's Disease
Dunah, A. W., Jeong, H., Griffin, A., Kim, Y.-M., Standaert, D. G., Hersch, S. M., Mouradian, M. M., Young, A. B., Tanese, N., & Krainc, D. (2002) · Science · doi:10.1126/science.1072613 · Cited by 708
Cha, J.-H. J., Kosinski, C. M., Kerner, J. A., Alsdorf, S. A., Mangiarini, L., Davies, S. W., Penney, J. B., Bates, G. P., & Young, A. B. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6480 · Cited by 504
Self-citationWhat do we really know about the ubiquitin-proteasome pathway in muscle atrophy?
Jagoe, R. T., & Goldberg, A. L. (2001) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/00075197-200105000-00003 · Cited by 399
Lione, L. A., Carter, R. J., Hunt, M. J., Bates, G. P., Morton, A. J., & Dunnett, S. B. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-23-10428.1999 · Cited by 384
Self-citationNeurodegenerative disorders associated with diabetes mellitus
Ristow, M. (2004) · Journal of Molecular Medicine · doi:10.1007/s00109-004-0552-1 · Cited by 352
Mouse models of Huntington's disease
Menalled, L. B., & Chesselet, M.-F. (2002) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01884-8 · Cited by 315
Formation of Polyglutamine Inclusions in Non-CNS Tissue
Sathasivam, K., Hobbs, C., Turmaine, M., Mangiarini, L., Mahal, A., Bertaux, F., Wanker, E. E., Doherty, P., Davies, S. W., & Bates, G. P. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.5.813 · Cited by 289
Self-citationWeight loss in early stage of Huntington’s disease
Djoussé, L., Knowlton, B., Cupples, L. A., Marder, K., Shoulson, I., & Myers, R. H. (2002) · Neurology · doi:10.1212/01.wnl.0000031791.10922.cf · Cited by 285
Orexin loss in Huntington's disease
Petersén, Å., Gil, J., Maat-Schieman, M. L. C., Björkqvist, M., Tanila, H., Araújo, I. M., Smith, R., Popovic, N., Wierup, N., Norlén, P., et al. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi004 · Cited by 271
Self-citationProgression of Symptoms in the Early and Middle Stages of Huntington Disease
Kirkwood, S. C., Su, J. L., Conneally, P. M., & Foroud, T. (2001) · Archives of Neurology · doi:10.1001/archneur.58.2.273 · Cited by 269
Stack, E. C., Kubilus, J. K., Smith, K., Cormier, K., Del Signore, S. J., Guelin, E., Ryu, H., Hersch, S. M., & Ferrante, R. J. (2005) · Journal of Comparative Neurology · doi:10.1002/cne.20680 · Cited by 246
Experimental therapeutics in transgenic mouse models of Huntington's disease
Beal, M. F., & Ferrante, R. J. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1386 · Cited by 222
Mice transgenic for an expanded CAG repeat in the Huntington's disease gene develop diabetes.
Hurlbert, M. S., Zhou, W., Wasmeier, C., Kaddis, F. G., Hutton, J. C., & Freed, C. R. (1999) · Diabetes · doi:10.2337/diabetes.48.3.649 · Cited by 218
Wong, E. Y. H., & Herbert, J. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2005.08.073 · Cited by 200
Adrenal Corticosteroid Biosynthesis, Metabolism, and Action
Arlt, W., & Stewart, P. M. (2005) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2005.01.002 · Cited by 195
CORTICOSTEROID MYOPATHY: A CLINICAL AND PATHOLOGICAL STUDY
KHALEELI, A. A., EDWARDS, R. H. T., GOHIL, K., McPHAIL, G., RENNIE, M. J., ROUND, J., & ROSS, E. J. (1983) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1983.tb03198.x · Cited by 190
Dopamine D1 and D2 receptor gene expression in the striatum in Huntington's disease
Augood, S. J., Faull, R. L. M., & Emson, P. C. (1997) · Annals of Neurology · doi:10.1002/ana.410420213 · Cited by 177
Atrophy of the Hypothalamic Lateral Tuberal Nucleus in Huntingtonʼs Disease
Kremer, H. P. H., Roos, R. A. C., Dingjan, G., Bots, G. T. A. M., & Maran, E. (1990) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199007000-00002 · Cited by 172
Diabetes mellitus in Huntington disease
Farrer, L. A. (1985) · Clinical Genetics · doi:10.1111/j.1399-0004.1985.tb00185.x · Cited by 170 · cited 2×
“Indeed, a number of endocrine abnormalities have been reported to occur in patients with HD, such as increased levels of corticosteroids (4,5) and a high incidence of diabetes mellitus (10–25%) (6).”
BackgroundReduced hippocampal neurogenesis in R6/2 transgenic Huntington's disease mice
Gil, J. M. A. C., Mohapel, P., Araújo, I. M., Popovic, N., Li, J.-Y., Brundin, P., & Petersén, Å. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.05.006 · Cited by 167
Self-citationStriatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease
Weeks, R. A., Piccini, P., Harding, A. E., & Brooks, D. J. (1996) · Annals of Neurology · doi:10.1002/ana.410400110 · Cited by 166
Ribchester, R. R., Thomson, D., Wood, N. I., Hinks, T., Gillingwater, T. H., Wishart, T. M., Court, F. A., & Morton, A. J. (2004) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2004.03783.x · Cited by 164
BODY WEIGHT AND DIETARY FACTORS IN HUNTINGTON'S DISEASE PATIENTS COMPARED WITH MATCHED CONTROLS
Sanberg, P. R., Fibiger, H. C., & Mark, R. F. (1981) · Medical Journal of Australia · doi:10.5694/j.1326-5377.1981.tb135681.x · Cited by 161 · cited 1×
“Interestingly, skeletal muscle atrophy has been described in HD patients despite a sufficient caloric intake (1), and a reduced body mass index is often seen even in asymptomatic patients (2).”
BackgroundLüesse, H., Schiefer, J., Spruenken, A., Puls, C., Block, F., & Kosinski, C. M. (2001) · Behavioural Brain Research · doi:10.1016/s0166-4328(01)00261-3 · Cited by 158
Glucocorticoid Hormone Action: An Overview
Baxter, J. D., & Rousseau, G. G. (1979) · Monographs on endocrinology · doi:10.1007/978-3-642-81265-1_1 · Cited by 151
Adinoff, B. H., Iranmanesh, A., Veldhuis, J. D., & Fisher, L. (1998) · PubMed Central · Cited by 150
Björkqvist, M., Fex, M., Renström, E., Wierup, N., Petersén, Å., Gil, J., Bacos, K., Popovic, N., Li, J.-Y., Sundler, F., et al. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi053 · Cited by 140
Self-citationKremer, H. P. H., Roos, R. A. C., Dingjan, G. M., Bots, G. T. A. M., Bruyn, G. W., & Hofman, M. A. (1991) · Neuroscience Letters · doi:10.1016/0304-3940(91)90443-w · Cited by 121
A Review of Neuropeptide and Neuroendocrine Dysregulation in Anorexia and Bulimia Nervosa
Bailer, U., & Kaye, W. (2003) · Current Drug Target -CNS & Neurological Disorders · doi:10.2174/1568007033338689 · Cited by 111
Validation and calibration of DEXA body composition in mice
Brommage, R. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00470.2002 · Cited by 96
Fain, J. N. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.2.145 · Cited by 87
Serum dehydroepiandrosterone and cortisol measurements in Huntington's chorea
Leblhuber, F., Peichl, M., Neubauer, C. J., Reisecker, F., Steinparz, F. X., Windhager, E., & Maschek, W. (1995) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(95)00114-h · Cited by 71
The limbic-hypothalamic-pituitary-adrenal axis in Huntington's disease
Heuser, I. J. E., Chase, T. N., & Mouradian, M. M. (1991) · Biological Psychiatry · doi:10.1016/0006-3223(91)90007-9 · Cited by 68
Absence of Dopaminergic Control on Melanotrophs Leads to Cushing's-Like Syndrome in Mice
Saiardi, A. (1998) · Molecular Endocrinology · doi:10.1210/me.12.8.1133 · Cited by 65
Asialoerythropoetin is not effective in the R6/2 line of Huntington's disease mice
Gil, J. M., Leist, M., Popovic, N., Brundin, P., & Petersén, Å. (2004) · BMC Neuroscience · doi:10.1186/1471-2202-5-17 · Cited by 64
Self-citationCote, T. E., Felder, R. A., Kebabian, J. W., Sekura, R. D., Reisine, T., & Affolter, H. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)38537-x · Cited by 56
Seizures as a Manifestation of Systemic Disease
Messing, R. O., & Simon, R. P. (1986) · Neurologic Clinics · doi:10.1016/s0733-8619(18)30963-0 · Cited by 54
Armanini, D., Vecchio, F., Basso, A., Milone, F. F., Simoncini, M., Fiore, C., Mattarello, M. J., Sartorato, P., & Karbowiak, I. (2003) · Endocrine · doi:10.1385/endo:22:2:113 · Cited by 47
Neuroendocrinology of Neurodegenerative Diseases
de Aguilar, J. G., René, F., Dupuis, L., & Loeffler, J. (2003) · Neuroendocrinology · doi:10.1159/000074445 · Cited by 24
Pardy, K., Carter, D., & Murphy, D. (1990) · Endocrinology · doi:10.1210/endo-126-6-2960 · Cited by 22
Cited by
Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease
Zuccato, C., Valenza, M., & Cattaneo, E. (2010) · Physiological Reviews · doi:10.1152/physrev.00041.2009 · Cited by 848
Björkqvist, M., Wild, E. J., Thiele, J., Silvestroni, A., Andre, R., Lahiri, N., Raibon, E., Lee, R. V., Benn, C. L., Soulet, D., et al. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20080178 · Cited by 650
Self-citationMechanisms of neurodegeneration in Huntington’s disease
Gil, J. M., & Rego, A. C. (2008) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06310.x · Cited by 471
Gubert, C., Kong, G., Renoir, T., & Hannan, A. J. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104621 · Cited by 363
Beyond the brain: widespread pathology in Huntington's disease
van der Burg, J. M., Björkqvist, M., & Brundin, P. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70178-4 · Cited by 363
Self-citation
Metadata
- Authors
- Björkqvist, M., Petersén, Å., Bacos, K., Isaacs, J., Norlén, P., Gil, J., Popovic, N., Sundler, F., Bates, G. P., Tabrizi, S. J., Brundin, P., & Mulder, H.
- Affiliations
- Lund University (SE)
- Corresponding author
- Björkqvist, Maria
- ORCID
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-04-13
- Volume
- 15
- Issue
- 10
- Pages
- 1713-1721
- ISSN
- 0964-6906 (ISSN-L)
- 1460-2083
- OpenAlex
- W2164413723
- Cited by
- 138
- References
- 48
- Citations by year
- 2025: 3 · 2024: 7 · 2023: 4 · 2022: 5 · 2021: 6 · 2020: 3 · 2019: 8 · 2018: 2 · 2017: 2 · 2016: 6 · 2015: 8 · 2014: 12 · 2013: 10 · 2012: 8
- FWCI
- 3.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Human Molecular Genetics (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Funders
- Wellcome Trust
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- Huntington's disease, R6/2 transgenic mice, hypothalamic-pituitary-adrenal axis, corticosterone, ACTH, dopamine D2 receptor, adrenal cortex hypertrophy, insulin resistance, bone mineral density, muscle atrophy, urinary cortisol, disease progression
- MeSH terms
- Huntingtin Protein, Adrenocorticotropic Hormone, Adult, Animals, Corticosterone, Disease Models, Animal, Dopamine, Female, Humans, Huntington Disease, Hydrocortisone, Hypothalamo-Hypophyseal System, Insulin Resistance, Male, Mice, Transgenic, Middle Aged, Muscular Atrophy, Nerve Tissue Proteins, Nuclear Proteins, Pituitary-Adrenal System, Bone Density, Receptors, Dopamine D2, Body Fat Distribution, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.